Try our beta test site

Study Assessing Immunogenicity and Safety of IC43 In Intensive Care Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Valneva Austria GmbH
ClinicalTrials.gov Identifier:
NCT00876252
First received: April 3, 2009
Last updated: October 18, 2012
Last verified: October 2012